Home › Markets › Health Care › AXSM

Axsome Therapeutics Inc. (AXSM)

AXSM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · October 14, 2026
$156.32
-5.83% on the day
Market cap
$8.2B
Mid cap
Revenue · 2025
$638.5M
+65.5% on 2024
Net income · 2025
-$183.2M
-28.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.

Profile

FieldValue
TickerAXSM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2015
SEC CIK0001579428
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$638.5M
Net income-$183.2M
Operating income-$166.8M
Net margin-28.7%
Operating margin-26.1%
Revenue growth+65.5%
Cash$322.9M
Total assets$689.8M
P/E (computed)Net income was not positive
P/S (computed)12.8×

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2025-11-03
Latest annual report10-K2026-02-23
Latest quarterly / interim10-Q2026-08-10
Latest current report8-K2026-08-10
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 670 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.2%
1 month-20.5%
3 months-31.5%
Year to date-11.1%
1 year+34.0%
From 52-week high-36.4%

Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ARWRArrowhead Pharmaceuticals Inc.$58.13-4.28%$8.2B
TGTXTG Therapeutics Inc.$54.34-1.68%$8.3B
CYTKCytokinetics Incorporated$61.62-1.86%$8.6B
ABVXAbivax SA$86.22-0.83%$7.5B
PTGXProtagonist Therapeutics Inc.$138.49-4.41%$9.0B
SYRESpyre Therapeutics Inc.$80.45-6.34%$7.1B
IONSIonis Pharmaceuticals Inc.$42.38-2.95%$7.0B
AMRXAmneal Pharmaceuticals Inc.$19.57-2.30%$6.8B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier